GoodRx Holdings, Inc. (GDRX) – What Are Brokerages Saying About This Stock?

GoodRx Holdings, Inc. (NASDAQ:GDRX) has been given an average recommendation of “Hold” by the thirteen ratings firms that are presently covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $4.23.

GDRX has been the subject of several research reports. Barclays upped their price target on shares of GoodRx from $3.00 to $4.00 and gave the company an “underweight” rating in a research report on Thursday, August 20th. Citigroup lifted their price objective on shares of GoodRx from $4.00 to $5.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. UBS Group upped their target price on shares of GoodRx from $2.50 to $3.75 and gave the company a “neutral” rating in a report on Thursday, August 13th. Leerink Partners set a $5.00 target price on shares of GoodRx in a research note on Thursday, August 6th. Finally, TD Cowen raised their price target on GoodRx from $4.00 to $5.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th.

GoodRx Trading Down 1.7%

NASDAQ:GDRX opened at $3.49 on Wednesday. The company has a market capitalization of $1.20 billion, a PE ratio of 87.27, a P/E/G ratio of 1.77 and a beta of 1.66. GoodRx has a 52-week low of $1.77 and a 52-week high of $3.89. The stock’s 50 day moving average price is $3.43 and its 200 day moving average price is $2.83. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.74.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.08 earnings per share for the quarter, meeting the consensus estimate of $0.08. The business had revenue of $200.41 million during the quarter, compared to the consensus estimate of $193.23 million. GoodRx had a return on equity of 7.22% and a net margin of 2.07%. The company’s revenue was down 1.3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.09 earnings per share. On average, research analysts anticipate that GoodRx will post 0.16 EPS for the current year.

Insiders Place Their Bets

In other GoodRx news, major shareholder Francisco Partners Iv, L.P. sold 1,296,177 shares of the stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $3.50, for a total transaction of $4,536,619.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last ninety days, insiders sold 2,760,995 shares of company stock worth $9,673,207. 5.87% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On GoodRx

Several hedge funds have recently modified their holdings of GDRX. Headlands Technologies LLC purchased a new position in GoodRx during the 2nd quarter worth $30,000. Essential Partners LLC boosted its holdings in shares of GoodRx by 375.4% in the first quarter. Essential Partners LLC now owns 14,304 shares of the company’s stock valued at $28,000 after acquiring an additional 11,295 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of GoodRx in the first quarter valued at about $29,000. Krilogy Financial LLC acquired a new position in shares of GoodRx during the first quarter worth about $33,000. Finally, Amundi acquired a new position in shares of GoodRx during the first quarter worth about $37,000. 63.77% of the stock is owned by institutional investors and hedge funds.

About GoodRx

GoodRx Holdings, Inc operates a digital healthcare platform that helps consumers find and access lower prices for prescription medications. Through its website and mobile applications, GoodRx allows users to compare prices at participating pharmacies, obtain prescription discount coupons and identify potential savings on commonly prescribed drugs. The company’s services are generally available at pharmacies across the United States.

GoodRx also offers GoodRx Gold, a membership program that provides additional discounts on eligible prescriptions, as well as healthcare-related content and tools designed to help consumers understand medications and treatment options.